Chugai Pharmaceutical Co., Ltd.
CHGCY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.54 | -2.03 | 0.62 | 0.50 |
| FCF Yield | 3.45% | 3.87% | 3.16% | 3.34% |
| EV / EBITDA | 18.90 | 17.47 | 9.31 | 13.19 |
| Quality | ||||
| ROIC | 20.09% | 19.50% | 25.88% | 25.03% |
| Gross Margin | 71.01% | 62.81% | 62.20% | 66.18% |
| Cash Conversion Ratio | 0.76 | 1.26 | 0.42 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.42% | 3.59% | 16.99% | 13.37% |
| Free Cash Flow Growth | 16.99% | 94.17% | -16.39% | 43.96% |
| Safety | ||||
| Net Debt / EBITDA | -0.92 | -0.95 | -0.37 | -0.56 |
| Interest Coverage | -527.75 | 0.00 | 8,742.77 | 8,789.52 |
| Efficiency | ||||
| Inventory Turnover | 1.41 | 1.51 | 1.63 | 1.62 |
| Cash Conversion Cycle | 292.11 | 246.93 | 211.61 | 190.70 |